Abstract
Immunity and inflammation are well established factors in the pathogenesis of pulmonary arterial hypertension (PAH). We aimed to investigate whether dexamethasone (Dex), a potent immunosuppressant, could prevent the development of monocrotaline (MCT)-induced PAH in rats as compared with pyrrolidine dithiocarbamate (PDTC) and its effect on the immune mechanism. PAH in rats (n = 66) was induced by MCT (50 mg/kg) injected intraperitoneally. Two days after MCT treatment, Dex (1.0 mg/kg) and PDTC (100 mg/kg) were administered once daily for 21 days. Samples were collected at 7, 14, and 21 days. Dex effectively inhibited MCT-induced PAH and reduced the T-helper (Th) 1 dominant cytokine response (interferon-γ) but up-regulated the Th2 one (interleukin 4). It increased the number of CD4+ T cells and decreased the number of CD8+ T cells around pulmonary arteries, upregulated the mRNA expression of fractalkine and downregulated that of CX3CR1 in the lung. Serum levels of interferon γ and interleukin 4 did not significantly differ from that of controls. Dex attenuated the process of MCT-induced PAH through its immunomodulatory property. Dex could be an appropriate therapy for PAH, although more studies are needed to define the appropriate treatment regimen.
Similar content being viewed by others
References
Tanino Y (2001) Monocrotaline-induced pulmonary hypertension in animals. Nippon Rinsho 59:1076–1080
Sawada H, Mitani Y, Maruyama J, Jiang BH, Ikeyama Y, Dida FA, Yamamoto H, Imanaka-Yoshida K, Shimpo H, Mizoguchi A, Maruyama K, Komada Y (2007) A nuclear factor-kappaB inhibitor pyrrolidine dithiocarbamate ameliorates pulmonary hypertension in rats. Chest 132:1265–1274
Dorfmüller P, Perros F, Balabanian K, Humbert M (2003) Inflammation in pulmonary arterial hypertension. Eur Respir J 22:358–363
Nicolls MR, Taraseviciene-Stewart L, Rai PR, Badesch DB, Voelkel NF (2005) Autoimmunity and pulmonary hypertension. Eur Respir J 26:1110–1118
Lederman MM, Sereni D, Simonneau G, Voelkel NF (2008) Pulmonary arterial hypertension and its association with HIV infection: an overview. AIDS 22:S1–S6
Chan SY, Loscalzo J (2008) Pathogenic mechanisms of pulmonary arterial hypertension. J Mol Cell Cardiol 44:14–30
Tuder RM, Cool CD, Yeager M, Taraseviciene-Stewart L, Bull TM, Voelkel NF (2001) The pathobiology of pulmonary hypertension. Endothelium. Clin Chest Med 22:405–418
Budhiraja R, Tuder RM, Hassoun PM (2004) Endothelial dysfunction in pulmonary hypertension. Circulation 109:159–165
Toshner M, Voswinckel R, Southwood M, Al-Lamki R, Howard LS, Marchesan D, Yang J, Suntharalingam J, Soon E, Exley A, Stewart S, Hecker M, Zhu Z, Gehling U, Seeger W, Pepke-Zaba J, Morrell NW (2009) Evidence for dysfunction of endothelial progenitors in pulmonary arterial hypertension. Am J Respir Crit Care Med 180:780–787
Foussat A, Coulomb-L’Hermine A, Gosling J, Krzysiek R, Durand-Gasselin I, Schall T, Balian A, Richard Y, Galanaud P, Emilie D (2000) Fractalkine receptor expression by T lymphocyte subpopulations and in vivo production of fractalkine in human. Eur J Immunol 30:87–97
Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A, Schall TJ (1997) A new class of membrane bound chemokine with a CX3C motif. Nature 385:640–644
Tuder RM, Groves B, Badesch DB, Voelkel NF (1994) Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 144:275–285
Taraseviciene-Stewart L, Scerbavicius DK, Burns N, Cool CD, Nicolls MR, Voelkel NF (2005) The protective role of T-lymphocytes in pulmonary vascular remodeling. Chest 128:571S–572S
Cupps TR, Fauci AS (1982) Corticosteroid-mediated immunoregulation in man. Immunol Rev 65:133–155
RamÃrez F, Fowell DJ, Puklavec M, Simmonds S, Mason D (1996) Glucocorticoids promote a TH2 cytokine response by CD4+ T cells in vitro. J Immunol 156:2406–2412
DeKruyff RH, Fang Y, Umetsu DT (1998) Corticosteroids enhance the capacity of macrophages to induce Th2 cytokine synthesis in CD4+ lymphocytes by inhibiting IL-12 production. J Immunol 160:2231–2237
Guo C, Chu X, Shi Y, He W, Li L, Wang L, Wang Y, Peng J, Hou M (2007) Correction of Th1-dominant cytokine profiles by high-dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura. J Clin Immunol 27:557–562
Romagnani S (1997) The Thl/Th2 paradigm. Immunol Today 18:263–266
Sanchez O, Humbert M, Sitbon O, Simonneau G (1999) Treatment of pulmonary hypertension secondary to connective tissue diseases. Thorax 54:273–277
Bellotto F, Chiavacci P, Laveder F, Angelini A, Thiene G, Marcolongo R (1999) Effective immunosuppressive therapy in a patient with primary pulmonary hypertension. Thorax 54:372–374
Liu SF, Ye X, Malik AB (1999) Inhibition of NF-kB activation by pyrrolidine dithiocarbamate prevents in vivo expression of proinflammatory genes. Circulation 100:1330–1337
Huang J, Kaminski PM, Edwards JG, Yeh A, Wolin MS, Frishman WH, Gewitz MH, Mathew R (2008) Pyrrolidine dithiocarbamate restores endothelial cell membrane integrity and attenuates monocrotaline-induced pulmonary artery hypertension. Am J Physiol Lung Cell Mol Physiol 294:L1250–L1259
Pahl HL (1999) Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18:6853–6866
Lee UJ, Choung SR, Prakash KV, Lee EJ, Lee MY, Kim YJ, Han CW, Choi YC (2008) Dual knockdown of p65 and p50 subunits of NF-kappaB by siRNA inhibits the induction of inflammatory cytokines and significantly enhance apoptosis in human primary synoviocytes treated with tumor necrosis factor-alpha. Mol Biol Rep 35:291–298
Schottelius AJ, Mayo MW, Sartor RB, Baldwin AS Jr (1999) Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding. J Biol Chem 274:31868–31874
Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr (1995) Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 270:283–286
Hilliker KS, Roth RA (1984) Alteration of monocrotaline pyrrole-induced cardiopulmonary effects in rats by hydrallazine, dexamethasone or sulphinpyrazone. Br J Pharmacol 82:375–380
Daley E, Emson C, Guignabert C, de Waal Malefyt R, Louten J, Kurup VP, Hogaboam C, Taraseviciene-Stewart L, Voelkel NF, Rabinovitch M, Grunig E, Grunig G (2008) Pulmonary arterial remodeling induced by a Th2 immune response. J Exp Med 205:361–372
Wilckens T, De Rijk R (1997) Glucocorticoids and immune function: unknown dimensions and new frontiers. Immunol Today 18:418–424
Pinto RF, Higuchi Mde L, Aiello VD (2004) Decreased numbers of T-lymphocytes and predominance of recently recruited macrophages in the walls of peripheral pulmonary arteries from 26 patients with pulmonary hypertension secondary to congenital cardiac shunts. Cardiovasc Pathol 13:268–275
Sakaguchi S, Yamaguchi T, Nomura T, Ono M (2008) Regulatory T cells and immune tolerance. Cell 133:775–787
Kumaraguru U, Banerjee K, Rouse BT (2005) In vivo rescue of defective memory CD8+ T cells by cognate helper T cells. J Leukoc Biol 78:879–887
Trzonkowski P, Szmit E, Myśliwska J, Myśliwski A (2006) CD4+CD25+ T regulatory cells inhibit cytotoxic activity of CTL and NK cells in humans impact of immunosenescence. Clin Immunol 119:307–316
Imaizumi T, Yoshida H, Satoh K (2004) Regulation of CX3CL1/fractalkine expression in endothelial cells. J Atheroscler Thromb 11:15–21
Perros F, Dorfmüller P, Souza R, Durand-Gasselin I, Godot V, Capel F, Adnot S, Eddahibi S, Mazmanian M, Fadel E, Hervé P, Simonneau G, Emilie D, Humbert M (2007) Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension. Eur Respir J 29:937–943
Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, Kakizaki M, Takagi S, Nomiyama H, Schall TJ, Yoshie O (1997) Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 91:521–530
Kagoshima M, Ito K, Cosio B, Adcock IM (2003) Glucocorticoid suppression of nuclear factor-kappa B: a role for histone modifications. Biochem Soc Trans 31:60–65
Hayashi R, Wada H, Ito K, Adcock IM (2004) Effects of glucocorticoids on gene transcription. Eur J Pharmacol 500:51–62
Faul JL, Nishimura T, Berry GJ, Benson GV, Pearl RG, Kao PN (2000) Triptolide attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respir Crit Care Med 162:2252–2258
Qiu D, Zhao G, Aoki Y, Shi L, Uyei A, Nazarian S, Ng JC, Kao PN (1999) Immunosuppressant PG490 (triptolide) inhibits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated T-cells and NF-kappaB transcriptional activation. J Biol Chem 274:13443–13450
Acknowledgments
The authors are grateful to Fengqin Liu and Qingqing Wang for excellent secretarial work. We also greatly appreciate the staff of the Central Laboratory of our hospital.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Fig. S1
Immunohistochemical analysis of macrophages in rat lungs. Sections were from control treatment (a), 1 week post-MCT treatment (b), 2 weeks post-MCT treatment (c), 3 weeks post-MCT treatment (d), PDTC treatment (e), Dex treatment (f). Positive-stained cells are brown. Magnification ×400 (JPEG 1227 kb)
Rights and permissions
About this article
Cite this article
Wang, W., Wang, Yl., Chen, Xy. et al. Dexamethasone attenuates development of monocrotaline-induced pulmonary arterial hypertension. Mol Biol Rep 38, 3277–3284 (2011). https://doi.org/10.1007/s11033-010-0390-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11033-010-0390-x